Auxogyn Announces Availability of Groundbreaking IVF Test, Eeva™, at Bourn Hall Clinic; Designed to Improve Outcomes

Tue May 7, 2013 8:30am EDT

* Reuters is not responsible for the content in this press release.

Auxogyn Announces Availability of Groundbreaking IVF Test, Eeva™, at Bourn Hall Clinic; Designed to Improve Outcomes

-- First Clinic in East England to Offer the Eeva Test --

The cutting-edge, new Early Embryo Viability Assessment™ (Eeva) Test designed to improve in vitro fertilization (IVF) outcomes is now available to couples seeking IVF treatment in East England. Using intelligent computer vision software to analyze key scientifically and clinically validated cell-division parameters, the Eeva Test is the first and only non-invasive IVF test clinically proven to help IVF teams determine which embryos have the best potential to grow to the blastocyst stage, a critical milestone in embryo development. With automated analysis of the early stages of the embryo’s development, the Eeva Test provides clinicians with objective and predictive information about the embryo’s developmental potential. It is now available at six clinics in Europe.

“As the world’s first IVF clinic, we are proud to be one of the first clinics in the world to offer the Eeva Test, further enhancing the likelihood of a positive outcome for our patients,” said Martyn Blayney, head of science at Bourn Hall. “The Eeva Test enables us to not only see the embryo during the early developmental stages, but also gives us a result on the developmental potential of the embryo based on factual, objective scientific evidence, not just on how the embryos look. This is something that has not been available until now and has the potential to truly change the way we select embryos.”

“Our goal in developing the Eeva test is to help couples achieve a successful pregnancy. With the expansion of Eeva throughout the UK, more couples will now have access to the first and only non-invasive test that delivers consistent, objective and actionable information to help identify viable embryos and determine which ones offer the greatest potential,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “We’ve seen great success from the clinics in the UK and Ireland already offering the Eeva Test and now couples in the East England area can also benefit from this new technology.”

Appointments for the new test are available from Bourn Hall by calling + 44 (0)1954 719111. Visit for further details.

About IVF

Infertility affects one out of every six couples in the UK. The demand for assisted reproduction tools and procedures is growing worldwide due to higher infertility rates caused by an increasing maternal age as more women are starting families later in life. This worldwide growth is occurring despite the significant cost per IVF cycle and the low success rate, with approximately one-third of cycles resulting in a live birth. This necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved.

About the Early Embryo Viability Assessment (Eeva) Test

The Eeva Test is designed to improve embryo selection by providing clinicians with objective information to more confidently select embryo(s) for transfer to help achieve better IVF outcomes. Eeva’s proprietary software automatically analyses embryo development against scientifically and clinically validated cell-division parameters discovered by researchers at Stanford University in the United States. The Eeva test not only provides novel quantitative information, but also ensures consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva’s quantitative data for each embryo’s potential development, IVF clinics may be able to optimize the treatment path for their patients undergoing IVF procedures. The effectiveness of the Eeva Test was validated in a prospective, multi-center, 54-patient clinical trial with 758 embryos. Embryologists using Eeva were significantly able to improve their ability to identify non-viable embryos relative to traditional methods. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey.

Eeva is currently CE Mark approved and available for use only in the EU and is pending FDA clearance in the United States. For more information about Eeva, visit or follow Eeva on Twitter @EevaIVF.

About Auxogyn

Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company’s flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that IVF clinicians and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit and follow us on Twitter @Auxogyn.

Jessica Volchok
(310) 774-3423